Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for vonoracin fumarate tablets approved and issued by the State Drug Administration. The specifications are 20 mg and 10 mg. The approval numbers are Sinopharm Standard H20265598 and Sinopharm Standard H20265599. The drug is used for reflux esophagitis, etc., and was approved for sale in China in December 2019. The market sales amount for the first quarter of 2026 was about 282 million yuan. The company invests about 4.22 million yuan in R&D. Approval will enrich the company's product line and enhance competitiveness, but production and sales are affected by policy, market and other factors, so investors need to be aware of risks.

Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for vonoracin fumarate tablets approved and issued by the State Drug Administration. The specifications are 20 mg and 10 mg. The approval numbers are Sinopharm Standard H20265598 and Sinopharm Standard H20265599. The drug is used for reflux esophagitis, etc., and was approved for sale in China in December 2019. The market sales amount for the first quarter of 2026 was about 282 million yuan. The company invests about 4.22 million yuan in R&D. Approval will enrich the company's product line and enhance competitiveness, but production and sales are affected by policy, market and other factors, so investors need to be aware of risks.